A new approach to disease-modifying drug trials in Parkinson's disease
(2013) In Journal of Clinical Investigation 123(6). p.2364-2365- Abstract
- Translating new findings in the laboratory into therapies for patients is a slow and expensive process. The development of therapies for neurodegenerative diseases is further complicated by the difficulty in determining whether the drug truly retards the slow degenerative process or provides only symptomatic benefit. In this issue, Aviles-Olmos et al. describe a first in Parkinson's disease (PD) patient study using a drug previously approved for diabetes treatment. In addition to suggesting that the drug may indeed be disease modifying in PD, their innovative approach suggests there may be more rapid and inexpensive avenues for testing novel therapies in PD.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3990336
- author
- Barker, Roger A. ; Stacy, Mark and Brundin, Patrik LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Clinical Investigation
- volume
- 123
- issue
- 6
- pages
- 2364 - 2365
- publisher
- The American Society for Clinical Investigation
- external identifiers
-
- wos:000320093100011
- scopus:84878566284
- pmid:23728166
- ISSN
- 0021-9738
- DOI
- 10.1172/JCI69690
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Neuronal Survival (013212041)
- id
- f8bf47ff-2810-41d1-a038-903d2cd85891 (old id 3990336)
- date added to LUP
- 2016-04-01 14:10:40
- date last changed
- 2022-03-29 19:34:42
@misc{f8bf47ff-2810-41d1-a038-903d2cd85891, abstract = {{Translating new findings in the laboratory into therapies for patients is a slow and expensive process. The development of therapies for neurodegenerative diseases is further complicated by the difficulty in determining whether the drug truly retards the slow degenerative process or provides only symptomatic benefit. In this issue, Aviles-Olmos et al. describe a first in Parkinson's disease (PD) patient study using a drug previously approved for diabetes treatment. In addition to suggesting that the drug may indeed be disease modifying in PD, their innovative approach suggests there may be more rapid and inexpensive avenues for testing novel therapies in PD.}}, author = {{Barker, Roger A. and Stacy, Mark and Brundin, Patrik}}, issn = {{0021-9738}}, language = {{eng}}, number = {{6}}, pages = {{2364--2365}}, publisher = {{The American Society for Clinical Investigation}}, series = {{Journal of Clinical Investigation}}, title = {{A new approach to disease-modifying drug trials in Parkinson's disease}}, url = {{https://lup.lub.lu.se/search/files/3828240/4173640.pdf}}, doi = {{10.1172/JCI69690}}, volume = {{123}}, year = {{2013}}, }